within Pharmacolibrary.Drugs.S_SensoryOrgans.S02D_OtherOtologicals.S02DA01_Lidocaine;

model Lidocaine_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.35,
    Cl = 1.2833333333333333e-05,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006333333333333333,
    Tlag = 600,
    Vdp = 0.0016,
    k12 = 1.0833333333333335e-05,
    k21 = 1.0833333333333335e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lidocaine_1</td></tr><tr><td>ATC code:</td><td>S02DA01_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.0</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lidocaine is a local anesthetic and antiarrhythmic drug used for the treatment of ventricular arrhythmias and for local anesthesia in various medical procedures. It acts by blocking sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. Lidocaine is widely approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Adult subjects, PK after oral administration.</p><h4>References</h4><ol><li><p>Bebawy, G, et al., &amp; Abdallah, OY (2024). Buccal lidocaine mucoadhesive patches for pediatrics&#x27; teething pain: overcoming possible hazards of oral gels. <i>Pharmaceutical development and technology</i> 29(8) 805–813. DOI:<a href=\"https://doi.org/10.1080/10837450.2024.2393729\">10.1080/10837450.2024.2393729</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39166264/\">https://pubmed.ncbi.nlm.nih.gov/39166264</a></p></li><li><p>Chow, MS, et al., &amp; Hilleman, D (1988). Propafenone: a new antiarrhythmic agent. <i>Clinical pharmacy</i> 7(12) 869–877. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3061720/\">https://pubmed.ncbi.nlm.nih.gov/3061720</a></p></li><li><p>Klotz, U (2007). Antiarrhythmics: elimination and dosage considerations in hepatic impairment. <i>Clinical pharmacokinetics</i> 46(12) 985–996. DOI:<a href=\"https://doi.org/10.2165/00003088-200746120-00002\">10.2165/00003088-200746120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18027986/\">https://pubmed.ncbi.nlm.nih.gov/18027986</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S02DA01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lidocaine_1;
